

CSD/BSE&NSE/BM/2024-25

July 12, 2024

**To**  
**The Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**Scrip Code: 543064**

**Scrip Symbol: SUVENPHAR**

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015**

.....

In furtherance to our disclosure dated June 13, 2024, we wish to inform you that Suven Pharmaceuticals Limited has acquired 51% of the share capital on a fully diluted basis (i.e., 67.5% of the present equity share capital) of Sapala Organics Private Limited.

We request you to take these documents on your records.

Thanking you,  
Yours faithfully,  
**For Suven Pharmaceuticals Limited**

**K. Hanumantha Rao**  
Company Secretary

## **Suven Pharmaceuticals Limited**

**Registered Office:** # 215 Atrium, C Wing, 8th Floor,  
819-821, Andheri Kurla Road, Chakala, Andheri East,  
Chakala Midc, Mumbai- 400093, Maharashtra, India  
Tel: 91 22 61539999

**Corporate Office:** # 202, A-Wing, Galaxy Towers,  
Plot No.1, Hyderabad Knowledge City, TSIC,  
Raidurg, Hyderabad - 500081 Telangana, India  
Tel: 91 40 2354 9414 / 3311

Email: [info@suvenpharm.com](mailto:info@suvenpharm.com) | Website: [www.suvenpharm.com](http://www.suvenpharm.com) | CIN: L24299MH2018PLC422236